Please login to the form below

Not currently logged in
Email:
Password:

SD-809

This page shows the latest SD-809 news and features for those working in and with pharma, biotech and healthcare.

FDA sets August review date for Teva's movement disorder drug

FDA sets August review date for Teva's movement disorder drug

With no approved therapies for TD, analysts have predicted that SD-809 could become a $600m-a-year product by 2020 and achieve blockbuster sales at peak. ... Teva needs that kind of return, having forked out $3.5bn for SD-809's developer Auspex Pharma in

Latest news

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    Teva's drug SD 809 for the treatment of Huntington's disease was part of the acquisition of Auspex at a cost of $3.5bn. ... Originally reported in DW Issue 57 [March 2015], Teva paid a 42% premium to acquire the company, which included other pipeline

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics